Adial pharmaceuticals to present at the h.c. wainwright bioconnect 2022 conference

Charlottesville, va., jan. 10, 2022 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil; adilw) (“adial” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that william stilley, chief executive officer of adial, will be presenting at the h.c. wainwright bioconnect 2022 conference being held virtually january 10-13, 2022.
ADIL Ratings Summary
ADIL Quant Ranking